EN DE
Watch Exlites Holdings International Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Exlites Holdings International Inc (EXHI) fair value: what the stock is really worth

As of Nov 4, 2026: fair value (intrinsic value) of Exlites Holdings International Inc stock $0.31, price $0.35, that is 12.7% below the price, quality 47 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EH Exlites Holdings International Inc logo Thin data Nov 10, 2026

Exlites Holdings International Inc

EXHI · US
Expensive, weak quality

Our calculation puts a fair price 13% below what the stock costs today.

Quality 47/100
Mixed Growth (revenue 3y −23.3 %/yr in USD)
Thin margins · 0.1% net margin (TTM)
Fair value $0.3055 · Overvalued
Negative free cash flow
Trails peers (0/9)
Narrow moat 8/100 · thin data
Thin data
Estimate⚠ Thinly traded
Watch Exlites Holdings International Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10.00 $0.0700 Fair Value $0.3055 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.0700 – $10.00 · fair‑value band $0.2291 – $0.3818 · the $0.3500 price screens above the $0.3055 fair value. As of Nov 10, 2026.

Follow Exlites Holdings International in your weekly email

Every Wednesday you see whether Exlites Holdings International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Exlites Holdings International, Inc. manufactures and distributes medical products. The company distributes and manufactures therapeutic pain, exercise, weight loss, and DVT prevention systems for use by patients.

Show moreShow less

It sells proprietary patented and patent pending health care products, such as deep vein thrombosis units, transcutaneous electrical nerve stimulation units, electronic muscle stimulation units, various bracing products, and other medical and consumer healthcare products.

The company also focuses on electric vehicle range extenders. The company was incorporated in 1979 and is based in Tampa, Florida.

Stock analysis

Exlites Holdings International Inc (EXHI) currently trades at $0.3500, while our estimate is $0.3055, 13% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.2291 (bear) to $0.3818 (bull), the price of $0.3500 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 1996: revenue and profit before it include the divested business. Growth is measured afresh from 1996.

Exlites Holdings International Inc reported revenue of $71.0K in FY2026 versus $9.4K in FY2016, a compound +22.4%/yr. Reported net income was −$43.5K in FY2026.

Key figures

Market cap $15.4M Micro · P/S ratio 1.64 · Net margin 0.1% · Return on assets (EBIT) −18.1% (3-year average) · Operating margin −8.2% · Free cash flow −$170K · Net cash $15.1K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 107% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −13%, EXHI screens richer than that median.

Fair Value

Bear $0.2291 Fair Value $0.3055 Bull $0.3818
Price $0.3500 · Downside -12.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 30
Are margins and returns getting better?
Cashflow 50
Do the profits arrive as real cash?
Financial strength 78
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 61
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 68
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 1996: revenue and profit before it include the divested business. Growth is measured afresh from 1996.
Revenue growth 1 year
−29.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−23.3%
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11.1% (1994) → −61.3% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

EXHI screens overvalued: fair value 13% below the price. Compare with McKesson Corporation →

Compare Exlites Holdings International Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks

Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −12.7% · Below median
Profitability
Return on assets −9.8% · Bottom 25%
Net margin (12 months) 0.1% · Bottom 25%
Operating margin (12 months) −8.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B 37.41× · Priciest 25%
P/S (12 months) 1.64× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)16 · sector 39
FUTURE (revenue growth)0 · sector 21
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 54

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$17.05 HK$51.15 +200% vs EXHI
Jointown Pharmaceutical Group 600998 ¥5.18 ¥11.56 +123% vs EXHI
Shanghai Pharmaceuticals Holding 601607 ¥16.44 ¥35.78 +118% vs EXHI
China National Medicines Corporation 600511 ¥28.70 ¥58.47 +104% vs EXHI
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.72 ¥26.64 +35% vs EXHI
Cencora, Inc COR $348.71 $341.58 −2% vs EXHI
Henry Schein, Inc HSIC $88.74 $78.69 −11% vs EXHI
McKesson Corporation MCK $1,083 $822.74 −24% vs EXHI
Galenica AG GALE CHF 90.05 CHF 61.79 −31% vs EXHI
Cardinal Health, Inc CAH $276.79 $163.14 −41% vs EXHI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Exlites Holdings International Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Exlites Holdings International Inc Fair Value". https://www.fairvalue-calculator.com/stock/EXHI

Frequently asked questions

Is Exlites Holdings International Inc (EXHI) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.3055 versus the last price from Nov 4, 2026 of $0.3500, about 13% lower (overvalued).
What is the fair value of EXHI?
Our estimate for Exlites Holdings International Inc is $0.3055 (as of Nov 10, 2026), built from audited fundamentals. Last price (from Nov 4, 2026): $0.3500.
What is the quality score of EXHI?
Exlites Holdings International Inc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Exlites Holdings International Inc (EXHI)?
Our calculated price target is the estimate of $0.3055 (as of Nov 10, 2026). Cautious scenario $0.2291, optimistic scenario $0.3818. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Exlites Holdings International Inc stock forecast for 2026?
Our estimate puts fair value at $0.3055, about 13% lower versus the last price from Nov 4, 2026 of $0.3500 (overvalued). Cautious scenario $0.2291, optimistic scenario $0.3818. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Exlites Holdings International Inc (EXHI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Exlites Holdings International Inc it is $0.3055 per share (as of Nov 10, 2026), against a price of $0.3500.
Is Exlites Holdings International Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, EXHI trades above its calculated fair value: price $0.3500, fair value $0.3055, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EXHI?
No. The price is what the market pays today ($0.3500); the fair value is what the company's own numbers justify ($0.3055). For Exlites Holdings International Inc the two are $0.0445 per share apart. That gap is exactly why we show both numbers side by side.
How much is Exlites Holdings International Inc worth?
The market values Exlites Holdings International Inc at about $15.4M (market capitalisation, as of Nov 10, 2026). Per share that is $0.3500; our models calculate a fair value of $0.3055 per share.
What do the bullish and bearish scenarios say about EXHI?
Our models span a range for Exlites Holdings International Inc: cautious scenario $0.2291, base $0.3055, optimistic $0.3818 per share (as of Nov 10, 2026, price $0.3500). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is EXHI from its 52-week high?
Exlites Holdings International Inc trades at $0.3500, about 41% below its 52-week high of $0.5980 and 107% above the low of $0.1690 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3055 is for.
Which stocks are comparable to Exlites Holdings International Inc?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Exlites Holdings International Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.3500, calculated fair value $0.3055 (−13%), Quality Score 47/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Exlites Holdings International Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Exlites Holdings International Inc (EXHI)?
The latest price we hold is from Nov 4, 2026 and stands at $0.3500. Our estimate is $0.3055, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Exlites Holdings International Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Exlites Holdings International Inc

How large is the market capitalisation of Exlites Holdings International Inc (EXHI)?
The market capitalisation of Exlites Holdings International Inc is $15.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Exlites Holdings International Inc (EXHI)?
The price-to-sales ratio of Exlites Holdings International Inc is 1.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Exlites Holdings International Inc (EXHI)?
The net margin of Exlites Holdings International Inc is 0.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Exlites Holdings International Inc (EXHI)?
On an EBIT basis the return on assets of Exlites Holdings International Inc is −18.1% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Exlites Holdings International Inc (EXHI)?
The operating margin of Exlites Holdings International Inc is −8.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Exlites Holdings International Inc (EXHI) generate?
The free cash flow of Exlites Holdings International Inc is −$170K (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Exlites Holdings International Inc (EXHI) hold?
Exlites Holdings International Inc holds more cash than debt, $15.1K net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Exlites Holdings International Inc in the live analysis

One click puts Exlites Holdings International Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.